EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative analysis of VEGFA gene expression and drug targeting in kidney renal clear cell carcinoma (KIRC)

Amukti Prasetyaning, Indah Ria

Scripta Medica · 2026 · 57 (1) · 27-37

DOI: 10.5937/scriptamed57-58933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scripta Medica, 2026. Verfasst von Amukti Prasetyaning und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Vascular endothelial growth factor A (VEGFA) plays an important role in angiogenesis and is known to have a strong association with the development of various types of cancer, including kidney renal clear cell carcinoma (KIRC). The purpose of this study was to analyse VEGFA expression in KIRC tissue, identify genes that have high expression correlation and explore the therapeutic potential of VEGFA through the identification of drugs that target it.

Methods

This study used a public data-based bioinformatics approach to evaluate VEGFA gene expression, identify genes that have similar expression patterns (co-expression) with it and examine the potential of drugs targeting VEGFA in KIRC. Data and analysis were obtained from various trusted databases, namely UALCAN, GEPIA, TCGA, TISIDB and DrugBank.

Results

VEGFA was found to be significantly higher expressed in KIRC tissue compared to normal tissue. Ten genes showed high expression correlation with VEGFA, namely RP1-261G23.7 , FLT1, ZNF395, COL23A1, RP11-255M6.1, PLVAP, EXOC3L2, ESM1, EGLN3 and HIF1A-AS2. In addition, VEGFA is known to be the target of various therapeutic agents such as ranibizumab, VEGF-AS, bevasiranib, gliclazide, SNS-032, denibulin, aflibercept, ABT-510, dalteparin and chondroitin sulphate, most of which have a mechanism of action in inhibiting angiogenesis.

Conclusion

VEGFA has the potential to be an important biomarker and therapeutic target in KIRC. The combination of gene expression analysis and drug data confirms the strategic value of VEGFA in the development of more effective antiangiogenic therapies.

Zitieren

APA

Prasetyaning, A., & Ria, I. (2026). Integrative analysis of VEGFA gene expression and drug targeting in kidney renal clear cell carcinoma (KIRC). Scripta Medica, 57(1), 27-37. https://doi.org/10.5937/scriptamed57-58933

Vancouver

Prasetyaning A, Ria I. Integrative analysis of VEGFA gene expression and drug targeting in kidney renal clear cell carcinoma (KIRC). Scripta Medica. 2026;57(1):27-37. doi:10.5937/scriptamed57-58933

BibTeX
@article{Prasetyaning2026,
  author = {Prasetyaning, Amukti and Ria, Indah},
  title = {Integrative analysis of VEGFA gene expression and drug targeting in kidney renal clear cell carcinoma (KIRC)},
  journal = {Scripta Medica},
  year = {2026},
  volume = {57},
  number = {1},
  pages = {27--37},
  doi = {10.5937/scriptamed57-58933}
}
Kostenlos starten →